|
π
|
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
26 auth.
J. Kochenderfer,
M. Dudley,
Sadik H. Kassim,
R. Somerville,
R. O. Carpenter,
M. Stetler-Stevenson,
J. Yang,
G. Phan,
M. Hughes,
R. Sherry,
M. Raffeld,
Steven R. Feldman,
Lily Lu,
Yong F Li,
L. Ngo,
...
A. Goy,
T. Feldman,
D. Spaner,
Michael L. Wang,
Clara C. Chen,
S. Kranick,
A. Nath,
Debbie-Ann N. Nathan,
K. Morton,
M. A. Toomey,
S. Rosenberg
|
10 |
2015 |
10
π
|
|
π
|
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
18 auth.
J. Kochenderfer,
M. Dudley,
S. Feldman,
W. Wilson,
D. Spaner,
I. Maric,
M. Stetler-Stevenson,
G. Phan,
M. Hughes,
R. Sherry,
...
J. Yang,
U. Kammula,
Laura Devillier,
R. Carpenter,
Debbie-Ann N. Nathan,
R. Morgan,
C. Laurencot,
S. Rosenberg
|
10 |
2012 |
10
π
|
|
π
|
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
17 auth.
A. Chanan-Khan,
K. Miller,
L. Musial,
D. Lawrence,
S. Padmanabhan,
K. Takeshita,
C. Porter,
D. Goodrich,
Z. Bernstein,
P. Wallace,
...
D. Spaner,
A. Mohr,
C. Byrne,
F. Hernandez-Ilizaliturri,
C. Chrystal,
P. Starostik,
M. Czuczman
|
8 |
2006 |
8
π
|
|
π¬
|
Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype1
R. Romieu-Mourez,
M. François,
M. Boivin,
M. Bouchentouf,
D. Spaner,
J. Galipeau
|
8 |
2009 |
8
π¬
|
|
π
|
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
17 auth.
Christine I. Chen,
P. Bergsagel,
Harminder K Paul,
W. Xu,
A. Lau,
N. Dave,
V. Kukreti,
E. Wei,
Chungyee Leung-Hagesteijn,
Zhi Hua Li,
...
Joseph M. Brandwein,
Mariela Pantoja,
J. Johnston,
S. Gibson,
Tiffany A. Hernandez,
D. Spaner,
S. Trudel
|
7 |
2011 |
7
π
|
|
π¦
|
Hypersensitivity to natural latex.
D. Spaner,
J. Dolovich,
S. Tarlo,
G. Sussman,
K. Buttoo
|
7 |
1989 |
7
π¦
|
|
π’
|
Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia
15 auth.
Y. Shi,
J. TomiΔ,
J. TomiΔ,
F. Wen,
S. Shaha,
A. Bahlo,
R. Harrison,
J. Dennis,
R. Williams,
B. Gross,
...
Sarah R Walker,
J. Zuccolo,
J. Deans,
G. Hart,
D. Spaner
|
7 |
2010 |
7
π’
|
|
π
|
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
10 auth.
S. Oppermann,
J. Ylanko,
Yonghong Shi,
S. Hariharan,
C. Oakes,
Patrick M. Brauer,
...
J. ZΓΊΓ±iga-PflΓΌcker,
B. Leber,
D. Spaner,
D. Andrews
|
6 |
2016 |
6
π
|
|
π
|
Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
7 auth.
Rochelle L Mandelcorn-Monson,
N. Shear,
Eddy Yau,
S. Sambhara,
B. Barber,
D. Spaner,
...
M. Debenedette
|
6 |
2003 |
6
π
|
|
π
|
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
10 auth.
J. Mangel,
H. Leitch,
J. Connors,
R. Buckstein,
K. Imrie,
D. Spaner,
...
M. Crump,
N. Pennell,
A. Boudreau,
N. Berinstein
|
6 |
2004 |
6
π
|
|
π
|
The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice.
7 auth.
Yanmei Li,
L. M. Vecchiarelli-Federico,
You-jun Li,
S. Egan,
D. Spaner,
M. Hough,
...
Y. Ben-David
|
6 |
2012 |
6
π
|
|
π¦
|
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia
D. Spaner,
A. Masellis,
D. Spaner
|
6 |
2007 |
6
π¦
|
